Use of warfarin in the patient with cancer.
Pangilinan
Joanna Maudlin
JM
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA. jamaudli@med.umich.edu
Pangilinan
Percival H
PH
Worden
Francis P
FP
D018712:Analgesics, Non-Narcotic / Q000009:adverse effects; D000740:Anemia / Q000139:chemically induced; D000925:Anticoagulants / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D019587:Dietary Supplements; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D019934:International Normalized Ratio; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced; D014859:Warfarin / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*
D018712:Analgesics, Non-Narcotic; D000925:Anticoagulants; D000970:Antineoplastic Agents; D014859:Warfarin